S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

$4.24
+0.37 (+9.56%)
(As of 03/28/2024 ET)
Today's Range
$3.86
$4.25
50-Day Range
$3.70
$14.26
52-Week Range
$3.48
$61.20
Volume
206,405 shs
Average Volume
358,044 shs
Market Capitalization
$1.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$480.00

Tenax Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11,220.8% Upside
$480.00 Price Target
Short Interest
Healthy
2.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Tenax Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($28.80) to ($6.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.21 out of 5 stars

TENX stock logo

About Tenax Therapeutics Stock (NASDAQ:TENX)

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Stock Price History

TENX Stock News Headlines

Tenax Therapeutics: Q4 Earnings Insights
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Former public company CEO now leads RTP firm
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
TENX: First Patient Enrolled
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
TENX: IND Clears Way for Phase III
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TENX
Employees
7
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$480.00
High Stock Price Target
$480.00
Low Stock Price Target
$480.00
Potential Upside/Downside
+11,900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-11,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$52.12 per share

Miscellaneous

Free Float
292,000
Market Cap
$1.20 million
Optionable
Not Optionable
Beta
2.29

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Christopher T. Giordano (Age 49)
    CEO, President & Director
    Comp: $442.12k
  • Dr. Stuart Rich M.D. (Age 74)
    Chief Medical Officer & Director
    Comp: $354.02k
  • Mr. Lawrence R. Hoffman CPA (Age 69)
    Esq., Interim Chief Financial Officer
  • Mr. Doug Randall
    Executive Vice President of Commercial & Business Operations
  • Dr. Douglas Hay
    Senior Vice President of Regulatory Affairs

TENX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings
or view top-rated stocks.

What is Tenax Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they anticipate the company's stock price to reach $480.00 in the next twelve months. This suggests a possible upside of 11,220.8% from the stock's current price.
View analysts price targets for TENX
or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2024?

Tenax Therapeutics' stock was trading at $21.9680 at the start of the year. Since then, TENX shares have decreased by 80.7% and is now trading at $4.24.
View the best growth stocks for 2024 here
.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 36,700 shares, a decrease of 49.4% from the February 29th total of 72,500 shares. Based on an average daily trading volume, of 333,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.2% of the shares of the company are sold short.
View Tenax Therapeutics' Short Interest
.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our TENX earnings forecast
.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) issued its earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) earnings per share for the quarter, missing analysts' consensus estimates of ($208.00) by $32.00.

When did Tenax Therapeutics' stock split?

Tenax Therapeutics's stock reverse split on the morning of Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (62.02%), Vanguard Group Inc. (62.43%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TENX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners